Nemaura Medical to Present at The LD 500 Virtual Conference
August 25 2020 - 7:38AM
Business Wire
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on developing
micro-systems-based wearable diagnostic devices and currently
commercializing sugarBEAT®, its non-invasive and flexible
continuous glucose monitor (“CGM”), together with BEAT™diabetes, a
planned health subscription service designed to help people with
Type 2 diabetes and prediabetes through personalized lifestyle
coaching, today announced that its CEO Dr. Faz Chowdhury will be
presenting at the LD 500 investor conference on Thursday, September
3, 2020 at 10:20 a.m. ET.
In the presentation, Dr. Chowdhury will provide insight into the
Company’s progress on product rollouts in the USA, Germany and UK,
as well as the use of its CGM and lactate monitoring solutions for
monitoring of disease progression in COVID-19 patients.
Register here: https://ld500.ldmicro.com/
"We have been waiting for this moment all year long. Due to
COVID, it has been nearly impossible for physical conferences to
even take place. I want to show the world that you can still learn,
have a great time, and see some of the most unique companies in the
capital markets today. All without having to step foot outside. For
the first time, LD Micro is accessible to everyone, and we are
honored to welcome you to one of the most trusted platforms in the
space.” stated Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View Nemaura Medical’s profile here:
http://www.ldmicro.com/profile/NMRD
About Nemaura Medical, Inc.:
Nemaura Medical Inc. (NMRD) is a medical technology company
developing micro-systems-based wearable diagnostic devices and
currently commercializing sugarBEAT®, and proBEAT™. sugarBEAT®, a
CE mark approved Class IIb medical device, is a non-invasive and
flexible continuous glucose monitor (CGM) providing actionable
insights derived from real time glucose measurements and daily
glucose trend data, which may help people with diabetes and
pre-diabetes to better manage, reverse and prevent the onset of
diabetes. Nemaura has also submitted a PMA application for
sugarBEAT® to the US FDA. proBEAT™ comprises a non-invasive glucose
monitor and a digital healthcare subscription service and is due to
be launched in the US as a general wellness product.
For more information visit: www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, the launch of
proBEAT™ in the US, risks related to regulatory status and the
failure of future development and preliminary marketing efforts,
Nemaura’s ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Nemaura and its
partners’ ability to develop, market and sell proBEAT™, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to both
proBEAT™ digital health, and sugarBEAT®. There can be no assurance
that the company will be able to reach a part of or any of the
global market for CGM with its products/services. The FDA reserves
the right to re-evaluate their decision that proBEAT™ qualifies as
a general wellness product should it become aware of any issues
such as skin irritation or other adverse events from the device, as
well as any misuse impacting patient safety, and any other reason
as the FDA may see fit at its discretion to determine the product
does not fit the definition of a general wellness product. These
and other risks and uncertainties are identified and described in
more detail in Nemaura’s filings with the United States Securities
and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the most recently completed fiscal year,
its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200825005538/en/
Investor Contact: Dave Gentry, CEO RedChip Companies Office:
1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024